pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,113 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1174Endpoints892BioPharma Dive344BioSpace307Fierce Biotech290onclive165raps106globenewswire health73
therapy area
allOncology7609Rare Disease1874Cardiology1743Immunology1482Hematology1323Vaccines1197Pulmonology
  • Capricor sues Nippon Shinyaku over pricing dispute for Duchenne cell therapy candidate
    Capricor Therapeutics announced it has filed a lawsuit against its Japanese partner Nippon Shinyaku. The suit alleges a flaw in the pricing terms of the distribution and commercialization agreemen…
    Endpoints · 4mo agoNegative↗ source
  • Calls grow for increased recruitment of men into nursing to address workforce shortages
    Men make up only about 12% of the nursing workforce in the United States. The demand for nurses is rising, with roughly 200,000 job openings expected each year as many current nurses retire. The…
    STAT · 4mo agoPositive↗ source
← prev
page 112 of 125
next →
fda recalls70
fda medwatch60
fda press38
1188
Psychiatry & CNS866
Ophthalmology496
Pain480
Endocrinology & Metabolism474
Infectious Disease444
Epidemiologist highlights surge of hantavirus misinformation after cruise ship outbreak
An outbreak of hantavirus tied to the cruise ship MV Hondius has generated serious health concerns, but online discussion has taken a different turn. Social media users quickly began sharing false…
STAT · 4mo agoPositive↗ source
  • Immunic appoints Michael Panzara as chief medical officer, coming from Neurvati Neurosciences
    STAT+ columnist Ed Silverman's weekly feature highlights recent personnel changes in pharma. This edition notes a new appointment at Immunic. Immunic has named Michael Panzara its new chief medica…
    STAT · 4mo agoNeutral↗ source
  • Met Gala outfits whimsically matched to biotech logos in annual tradition
    The piece highlights an annual tradition of pairing Met Gala attire with the logos of biotech companies, a playful feature in the STAT newsletter The Readout. For this year’s event, whose theme wa…
    STAT · 4mo agoNeutral↗ source
  • Sarepta's Elevidys sales beat forecasts but dip again, prompting stock slide and shift to RNA pipeline
    Sarepta Therapeutics reported that its gene therapy Elevidys generated net product revenue that exceeded Wall Street estimates for the first quarter. However, sales continued to decline compared wi…
    BioPharma Dive · 4mo agoEarningsNegative↗ source
  • Astellas reports promising early results for stem cell eye therapy ASP7317 in age-related disease
    Astellas announced data from an early-stage trial of ASP7317, a stem cell-derived therapy aimed at an age-related eye condition. The study showed encouraging signs of efficacy and safety in most p…
    Endpoints · 4mo agoPositive readoutPositive↗ source
  • AI-generated fake citations surge, study finds they are polluting scientific literature
    A new study published in The Lancet reports a sharp rise in fabricated citations that do not correspond to real papers, threatening the reliability of the scientific record. The researchers found…
    STAT · 4mo agoNegative↗ source
  • WHO briefs on hantavirus outbreak aboard cruise ship, Spain to allow docking in Canary Islands
    WHO held a press conference Thursday to update on a suspected hantavirus outbreak on the cruise ship MV Hondius. The vessel is expected to dock in Tenerife, Canary Islands, after Spain agreed to t…
    STAT · 4mo agoNeutral↗ source
  • Seaport Therapeutics goes public as obesity drug race heats up and FDA commissioner faces White House scrutiny
    Seaport Therapeutics announced a successful initial public offering, with CEO Daphne Zohar discussing the company’s next steps on the latest Readout LOUD podcast. The episode also highlighted the…
    STAT · 4mo agoNeutral↗ source
  • Study finds researchers become less disruptive as they age, favoring incremental work
    A new study published in Science reports that scientists tend to produce their most disruptive work early in their careers, but shift toward less groundbreaking research as they get older. The ana…
    STAT · 4mo agoNeutral↗ source
  • Amazon adds Ozempic pill to same-day prescription drug kiosks
    The Ozempic pill is coming to Amazon Pharmacy’s prescription drug kiosks. It’s an expansion for the kiosks, which operate like vending machines and have been stocking oral Wegovy since February. Am…
    Endpoints · 4mo ago↗ source
  • Official leading CDC’s cruise ship program retires
    The hantavirus outbreak on the MV Hondius has focused the public's attention on cruise ship safety.
    STAT · 4mo ago↗ source
  • EnGene's shares crash on updated pivotal bladder cancer data
    EnGene’s latest Phase 2 results on an experimental treatment for certain bladder cancer patients alarmed investors and raised concerns around the therapy’s future prospects. The Canadian biotech's…
    Endpoints · 4mo ago↗ source
  • Are health insurers out of the woods after a tough 2025?
    Last year, health insurer after health insurer slashed or withdrew their profit outlooks after being sucker-punched by high medical costs. This year is shaping up ...
    Endpoints · 4mo ago↗ source
  • Blackstone puts $250M into Anagram to tackle cystic fibrosis complication
    Blackstone Life Sciences, fresh off one of the largest private investment funds in industry history, is putting $250 million to work on a little-known biotech seeking to drastically reduce the numb…
    Endpoints · 4mo ago↗ source
  • Angelini to buy Catalyst in $4B play for rare neuro drugs
    The acquisition hands the Italian pharma a group of medicines approved to treat various CNS disorders and gives it wider market access in the U.S.
    BioPharma Dive · 4mo ago↗ source
  • Entrada shares dive as Duchenne results disappoint
    While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.
    BioPharma Dive · 4mo ago↗ source
  • Entrada stock falls on Duchenne data; Wegovy expands access
    Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial data in six patients who received the low dose of its exon 44 skipping drug ...
    Endpoints · 4mo ago↗ source
  • Roche to acquire digital pathology firm PathAI in deal potentially worth over $1B
    Roche plans to offer PathAI’s tools as part of an effort to improve cancer diagnosis and tailored treatment.
    BioPharma Dive · 4mo ago↗ source
  • STAT+: More political interference at the FDA?
    A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newsletter.
    STAT · 4mo ago↗ source
  • Amgen adds $300M to Puerto Rico budget; Novartis to exit oral drug factory in Germany
    Plus, news about FDA's one-day inspections and BioMADE: 🇵🇷 Amgen pours another $300M into Puerto Rico: The funds will be used to bolster its biologics production in Juncos, which was established ...
    Endpoints · 4mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
    Sanofi asked the FDA to pull teplizumab out of a speedy review voucher program after a political appointee disagreed with staff over its approval
    STAT · 4mo ago↗ source
  • STAT+: FDA revisits a rare cancer treatment it rejected a few months ago
    Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout
    STAT · 4mo ago↗ source
  • Atara, Pierre Fabre's cell therapy to get another shot at FDA approval
    There's new life for a twice-rejected T cell therapy from Atara Biotherapeutics and Pierre Fabre Pharmaceuticals. US regulators are willing to reconsider using a Phase 3 study as the basis for an a…
    Endpoints · 4mo ago↗ source